65 results
6-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
9 Aug 06
Adherex Reports Second Quarter 2006 Financial Results
12:00am
,” said William P. Peters, MD, PhD, Chairman and CEO. “Recruitment in our Phase II single agent ADH-1 trials continues on target for completion by the end … positive non-small cell lung cancer and ovarian cancer. The Company expects this trial to complete recruitment in the fourth quarter of 2006 and also
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
7 Jan 13
Adherex Announces Completion of Patient Enrollment and Maintains TSX Listing Status
12:00am
(Treatment Arm X).Enrollment in the study exceeded initial recruitment expectations. The Company expanded the initial enrollment target from 140 patients
6-K
EX-99.3
FENC
Fennec Pharmaceuticals Inc
9 Aug 06
Adherex Reports Second Quarter 2006 Financial Results
12:00am
in patients with N-cadherin positive non-small cell lung cancer and ovarian cancer. We expect this trial to complete recruitment near the end of 2006 … every week from once every three weeks. We expect this trial to complete recruitment in the second half of 2006. Decisions regarding a single agent
6-K
ls2 2u0kjhlq59
21 Mar 05
Current report (foreign)
12:00am
6-K
EX-99.1
b4vnmjk8p4rluilv3
21 Mar 05
Current report (foreign)
12:00am
8-K
EX-99.1
ghmodk5ftuo
14 Mar 19
Fennec Provides Business Update and Announces Fiscal Year 2018 Financial Results
6:02am
6-K
tpds39m79ooy
12 Nov 04
Current report (foreign)
12:00am